RxDoctor Payments Data

Adrienne Laverdure, MD

Family Medicine · Woodruff, WINPI 1639119225

Payments from drug & device makers

$459in general payments, 2019–2025

Across 17 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$120
  • Alkermes, Inc.$104
  • Exact Sciences$101
  • Novo Nordisk$61
  • Merck$42
  • Indivior Inc.$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$44497%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$459 in reported general payments places this provider in the 80th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$33,884
Medicare patients
184
Services billed
1,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide79$74,638
OzempicSemaglutide46$44,772
FarxigaDapagliflozin Propanediol35$39,718
EliquisApixaban31$25,356
XareltoRivaroxaban18$16,262
JardianceEmpagliflozin18$16,023
Atorvastatin Calcium196$7,416
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$7,376
Venlafaxine Hcl ErVenlafaxine Hcl15$7,361
Combivent RespimatIpratropium/Albuterol Sulfate12$6,386
Rosuvastatin Calcium57$5,297
Humalog Kwikpen U-100Insulin Lispro26$5,086
Advair HfaFluticasone Propion/Salmeterol13$4,594
DuleraMometasone/Formoterol14$4,532
Montelukast Sodium30$4,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$44,77246 claims
PfizerEliquis$16$25,35631 claims
MerckDulera$42$4,53214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Woodruff

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →